Victory Capital Management Inc. lowered its position in STAAR Surgical (NASDAQ:STAA) by 63.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,983 shares of the medical instruments supplier’s stock after selling 3,444 shares during the period. Victory Capital Management Inc.’s holdings in STAAR Surgical were worth $58,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of STAA. TRUE Private Wealth Advisors purchased a new position in shares of STAAR Surgical in the 2nd quarter worth approximately $36,000. Aperio Group LLC acquired a new stake in STAAR Surgical in the 2nd quarter worth approximately $43,000. DekaBank Deutsche Girozentrale acquired a new stake in STAAR Surgical in the 2nd quarter worth approximately $46,000. AdvisorNet Financial Inc boosted its stake in STAAR Surgical by 54.8% in the 2nd quarter. AdvisorNet Financial Inc now owns 1,742 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 617 shares in the last quarter. Finally, Cutler Group LP acquired a new stake in STAAR Surgical in the 2nd quarter worth approximately $67,000. 90.87% of the stock is currently owned by hedge funds and other institutional investors.
STAA has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. ValuEngine upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating in a research note on Friday. Finally, BidaskClub cut shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $36.00.
STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Wednesday, July 31st. The medical instruments supplier reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.04. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $40.10 million. STAAR Surgical had a net margin of 5.80% and a return on equity of 12.81%. On average, equities research analysts expect that STAAR Surgical will post 0.32 earnings per share for the current year.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
See Also: What is the Dividend Aristocrat Index?
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.